Vericel Corporation will present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET.
Quiver AI Summary
Vericel Corporation, a leader in advanced therapies for sports medicine and severe burn care, announced its upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. The presentation will be available via webcast on the company's Investor Relations website. Vericel focuses on innovative therapies, offering products like MACI®, an autologous scaffold for knee cartilage repair, and Epicel®, a skin replacement for severe burns. The company also holds the North American rights to NexoBrid®, a product for burn treatment. More information about Vericel and its products can be found on their website.
Potential Positives
- Vericel Corporation will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among key investors and industry stakeholders.
- The company highlights its leadership in advanced therapies for sports medicine and severe burn care, showcasing its commitment to innovation in the healthcare space.
- Vericel's portfolio includes recognized products like MACI® and Epicel®, which address important medical needs and demonstrate the company's strong market position.
- The webcast of the presentation will make the information accessible to a wider audience, potentially attracting more interest in the company's therapeutic offerings.
Potential Negatives
- None
FAQ
When is Vericel Corporation presenting at the J.P. Morgan Healthcare Conference?
Vericel Corporation will present at the conference on January 14, 2026, at 2:15 p.m. ET.
Where can I watch the Vericel presentation?
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website.
What products does Vericel Corporation market?
Vericel markets MACI®, Epicel®, and holds rights to NexoBrid® for advanced therapies in sports medicine and burn care.
What is the focus of Vericel's therapies?
Vericel focuses on advanced therapies for sports medicine and severe burn care, utilizing biological and medical technologies.
What are the trademarks associated with Vericel Corporation?
Epicel®, MACI®, MACI Arthro®, and NexoBrid® are registered trademarks associated with Vericel Corporation and its licensed products.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VCEL Insider Trading Activity
$VCEL insiders have traded $VCEL stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $VCEL stock by insiders over the last 6 months:
- KEVIN F MCLAUGHLIN has made 0 purchases and 2 sales selling 14,000 shares for an estimated $521,570.
- JONATHAN MARK HOPPER (Chief Medical Officer) has made 0 purchases and 2 sales selling 11,652 shares for an estimated $422,359.
- MICHAEL HALPIN (Chief Operating Officer) has made 0 purchases and 2 sales selling 10,000 shares for an estimated $404,541.
- PAUL K WOTTON has made 0 purchases and 2 sales selling 5,000 shares for an estimated $189,500.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VCEL Revenue
$VCEL had revenues of $67.5M in Q3 2025. This is an increase of 16.58% from the same period in the prior year.
You can track VCEL financials on Quiver Quantitative's VCEL stock page.
$VCEL Hedge Fund Activity
We have seen 110 institutional investors add shares of $VCEL stock to their portfolio, and 145 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVESCO LTD. removed 1,247,893 shares (-62.6%) from their portfolio in Q3 2025, for an estimated $39,271,192
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,048,864 shares (+90.3%) to their portfolio in Q3 2025, for an estimated $33,007,750
- NEW YORK STATE COMMON RETIREMENT FUND removed 874,932 shares (-98.3%) from their portfolio in Q3 2025, for an estimated $27,534,110
- BROWN CAPITAL MANAGEMENT LLC removed 861,020 shares (-30.6%) from their portfolio in Q3 2025, for an estimated $27,096,299
- NEXT CENTURY GROWTH INVESTORS LLC removed 668,649 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,042,384
- FMR LLC removed 456,301 shares (-18.4%) from their portfolio in Q3 2025, for an estimated $14,359,792
- SOLEUS CAPITAL MANAGEMENT, L.P. added 447,000 shares (+877.3%) to their portfolio in Q3 2025, for an estimated $14,067,090
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VCEL Analyst Ratings
Wall Street analysts have issued reports on $VCEL in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 12/18/2025
- Canaccord Genuity issued a "Buy" rating on 08/01/2025
To track analyst ratings and price targets for $VCEL, check out Quiver Quantitative's $VCEL forecast page.
$VCEL Price Targets
Multiple analysts have issued price targets for $VCEL recently. We have seen 2 analysts offer price targets for $VCEL in the last 6 months, with a median target of $51.5.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $45.0 on 12/18/2025
- Caitlin Cronin from Canaccord Genuity set a target price of $58.0 on 08/01/2025
Full Release
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44 th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI ® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel ® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid ® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com .
Epicel ® and MACI ® and MACI Arthro ® are registered trademarks of Vericel Corporation. NexoBrid ® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
[email protected]
+1 (734) 418-4411
